You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 18, 2025

Drug Price Trends for HM SINUS SEVERE CAPLET


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for HM SINUS SEVERE CAPLET

Average Pharmacy Cost for HM SINUS SEVERE CAPLET

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
HM SINUS SEVERE CAPLET 62011-0240-01 0.10857 EACH 2024-08-21
HM SINUS SEVERE CAPLET 62011-0240-01 0.11551 EACH 2024-07-17
HM SINUS SEVERE CAPLET 62011-0240-01 0.11121 EACH 2024-06-19
HM SINUS SEVERE CAPLET 62011-0240-01 0.10751 EACH 2024-05-22
HM SINUS SEVERE CAPLET 62011-0240-01 0.12002 EACH 2024-04-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for HM Sinus Severe Caplets

Market Overview of Sinus Therapeutic Drugs

The global sinus therapeutic drug market is a growing sector, driven by the increasing prevalence of sinusitis and other respiratory allergies. As of 2023, the market size is estimated to be around USD 4.4 billion and is projected to grow to USD 6.3 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period from 2024 to 2033[3].

Product Details: HM Sinus Severe Caplets

While the specific product "HM Sinus Severe Caplets" is not detailed in the sources, we can analyze similar products like TYLENOL® Sinus Severe Daytime Caplets to understand the market dynamics.

TYLENOL® Sinus Severe Daytime Caplets are designed to alleviate symptoms associated with hay fever, other respiratory allergies, and the common cold. These caplets contain:

  • Acetaminophen 325 mg: Pain reliever and fever reducer
  • Guaifenesin 200 mg: Expectorant to help loosen phlegm and thin bronchial secretions
  • Phenylephrine HCl 5 mg: Nasal decongestant to relieve sinus congestion and pressure[1][2][4].

Market Segmentation

Drug Class Analysis

The sinus therapeutic drug market is segmented by drug class, with antibiotics holding a dominant position, accounting for approximately 29.1% of the market share. Other significant segments include analgesics, antihistamines, and corticosteroids[3].

Disease Type Analysis

Acute sinusitis is the most prevalent type, commanding a significant 37% market share. Sub-acute and chronic sinusitis also constitute substantial portions of the market[3].

Route of Administration Analysis

Oral administration is the most common route, holding about 34.2% of the market share. Topical and injectable routes also play important roles[3].

Distribution Channel Analysis

Retail pharmacies are the dominant distribution channel, accounting for around 34% of the market share. Hospital pharmacies and online pharmacies are other significant channels[3].

Regional Analysis

North America dominates the market with a 33.2% share and holds USD 1.4 billion in market revenue. This is due to the high prevalence of sinusitis, advanced diagnostic technologies, and a high level of disease awareness among patients and medical professionals. The Asia-Pacific region is expected to be the fastest-growing due to increasing awareness and rising air pollution levels[3].

Price Projections and Market Trends

Given the growing demand and expanding market size, prices for sinus therapeutic drugs, including HM Sinus Severe Caplets, are likely to remain stable or see moderate increases.

Factors Influencing Prices

  • Raw Material Costs: Fluctuations in the cost of active ingredients like acetaminophen, guaifenesin, and phenylephrine can impact the final product price.
  • Regulatory Changes: The FDA's proposed order to remove oral phenylephrine from the OTC monograph, though not related to safety, could influence production costs and pricing strategies[1][2][4].
  • Market Competition: The presence of multiple players in the market, such as Novartis AG, Sun Pharmaceutical Industries, and Reddy’s Laboratories, can lead to competitive pricing[3].

Consumer Feedback and Demand

Consumer reviews indicate a strong demand for effective over-the-counter (OTC) sinus relief medications. Products like TYLENOL® Sinus Severe Daytime Caplets are praised for their fast-acting relief and effectiveness, which can drive sales and stabilize or increase prices[2][4].

Key Takeaways

  • The global sinus therapeutic drug market is expected to grow from USD 4.4 billion in 2023 to USD 6.3 billion by 2033.
  • Oral administration and retail pharmacies are dominant in the market.
  • Acute sinusitis is the most prevalent disease type treated.
  • Regulatory changes and raw material costs can influence pricing.
  • Consumer demand for effective OTC sinus relief medications is strong.

FAQs

Q: What are the active ingredients in HM Sinus Severe Caplets? A: While specific details for HM Sinus Severe Caplets are not provided, similar products typically contain acetaminophen, guaifenesin, and phenylephrine.

Q: How often can I take HM Sinus Severe Caplets? A: For similar products, the recommended dosage is 2 caplets every 4 hours, not exceeding 10 caplets in 24 hours.

Q: What are the potential side effects of HM Sinus Severe Caplets? A: Potential side effects include liver damage if taken in excess, severe skin reactions, and interactions with other medications.

Q: Can I take HM Sinus Severe Caplets if I have liver disease? A: It is advised to consult a doctor before use if you have liver disease or any other serious health conditions.

Q: Are HM Sinus Severe Caplets safe for pregnant or breastfeeding women? A: Pregnant or breastfeeding women should consult a health professional before using this product.

Sources:

  1. TYLENOL® Sinus Severe Daytime Caplets - Product Details[1].
  2. TYLENOL® Sinus Severe Daytime Caplets - Reviews and Product Information[2].
  3. Global Sinus Therapeutic Drug Market - Market Report[3].
  4. TYLENOL® Sinus Severe Daytime Caplets - Consumer Reviews[4].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.